Clinical impact of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic cancer: diagnosing lymph node metastasis and predicting survival

被引：16
作者：
Kim, Hyung Rae [1 ]
Seo, Minjung [2 ]
Nah, Yang Won [3 ]
Park, Hyung Woo [3 ]
Park, Seol Hoon [2 ]
机构：
[1] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Internal Med, Ulsan, South Korea
[2] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Nucl Med, 877 Bangeojinsunhwan Doro, Ulsan 681714, South Korea
[3] Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Surg, Ulsan, South Korea
来源：
NUCLEAR MEDICINE COMMUNICATIONS | 2018年 / 39卷 / 07期
关键词：
disease-free survival; fluorine-18-fluorodeoxyglucose positron emission tomography; computed tomography; lymph node metastasis; lymph node to tumor standardized uptake value ratio; overall survival; pancreatic cancer; CELL LUNG-CANCER; STANDARDIZED UPTAKE VALUE; UPTAKE VALUE SUVMAX; PRIMARY TUMOR SUV; FDG-PET; F-18-FDG PET/CT; BREAST-CANCER; DUCTAL ADENOCARCINOMA; COMPUTED-TOMOGRAPHY; ESOPHAGEAL CANCER;
D O I：
10.1097/MNM.0000000000000855
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
PurposeTo evaluate the diagnostic accuracy of fluorine-18-fluorodeoxyglucose PET/computed tomography (F-18-FDG PET/CT) for lymph node (LN) metastasis and the prognostic significance of F-18-FDG PET/CT LN parameters in patients with resectable pancreatic cancer.Patients and methodsPatients with resectable pancreatic cancer who underwent staging F-18-FDG PET/CT between May 2007 and September 2016 were retrospectively enrolled and analyzed through medical record and image re-evaluation. The diagnostic accuracy of F-18-FDG PET/CT in predicting LN metastasis was evaluated and compared with that of contrast-enhanced abdominal computed tomography (CECT). Prognostic variables, including LN parameters assessed by F-18-FDG PET/CT [standardized uptake value (SUV)(LN) and LN/tumor SUV ratio], that affect disease-free survival (DFS) and overall survival (OS) were evaluated by regression analysis.ResultsWhen predicting LN metastasis, F-18-FDG PET/CT showed greater sensitivity, positive predictive value, negative predictive value, and accuracy than CECT. Among prognostic factors affecting DFS, PET-positive LN (P=0.008), and LN/tumor SUV ratio (P=0.003) were found to be significant by regression analysis. Among the variables affecting OS, lymphovascular invasion (P=0.018) and the LN/tumor SUV ratio (P=0.046) were found to be significant.Conclusion(18)F-FDG PET/CT showed higher diagnostic accuracy in predicting LN metastasis than CECT in patients with resectable pancreatic cancer. Only the LN/tumor SUV ratio of F-18-FDG PET/CT was an independent prognostic variable in both DFS and OS.
引用
收藏
页码：691 / 698
页数：8
相关论文
共 38 条
[1]   Non-small cell lung cancer: Dual-modality PET/CT in preoperative staging [J].
Antoch, G ;
Stattaus, J ;
Nemat, AT ;
Marnitz, S ;
Beyer, T ;
Kuehl, H ;
Bockisch, A ;
Debatin, JF ;
Freudenberg, LS .
RADIOLOGY, 2003, 229 (02) :526-533
[2]   Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline [J].
Balaban, Edward P. ;
Mangu, Pamela B. ;
Khorana, Alok A. ;
Shah, Manish A. ;
Mukherjee, Somnath ;
Crane, Christopher H. ;
Javle, Milind M. ;
Eads, Jennifer R. ;
Allen, Peter ;
Ko, Andrew H. ;
Engebretson, Anitra ;
Herman, Joseph M. ;
Strickler, John H. ;
Benson, Al B., III ;
Urba, Susan ;
Yee, Nelson S. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (22) :2654-U169
[3]   F-18 FLUORODEOXYGLUCOSE PET IN-VIVO EVALUATION OF PANCREATIC GLUCOSE-METABOLISM FOR DETECTION OF PANCREATIC-CANCER [J].
BARES, R ;
KLEVER, P ;
HAUPTMANN, S ;
HELLWIG, D ;
FASS, J ;
CREMERIUS, U ;
SCHUMPELICK, V ;
MITTERMAYER, C ;
BULL, U .
RADIOLOGY, 1994, 192 (01) :79-86
[4]   Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC) -: A systematic review and meta-analysis (MA) by the European lung cancer working party for the IASLC lung cancer staging project [J].
Berghmans, Thierry ;
Dusart, Michele ;
Paesmans, Marianne ;
Hossein-Foucher, Claude ;
Buvat, Irene ;
Castaigne, Catherine ;
Scherpereel, Arnaud ;
Mascaux, Celine ;
Moreau, Michel ;
Roelandts, Martine ;
Alard, Stphane ;
Meert, Anne-Pascale ;
Patz, Edward F., Jr. ;
Lafitte, Jean-Jacques ;
Sculier, Jean-Paul .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (01) :6-12
[5]   Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer [J].
Cerfolio, Robert James ;
Bryant, Ayesha S. .
ANNALS OF THORACIC SURGERY, 2007, 83 (05) :1826-1830
[6]   Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion [J].
Chen, John W. C. ;
Bhandari, Mayank ;
Astill, David S. ;
Wilson, Thomas G. ;
Kow, Lilian ;
Brooke-Smith, Mark ;
Toouli, James ;
Padbury, Robert T. A. .
HPB, 2010, 12 (02) :101-108
[7]   Prognostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Resectable Pancreatic Cancer [J].
Choi, Hye Jin ;
Kang, Chang Moo ;
Lee, Woo Jung ;
Song, Si Young ;
Cho, Arthur ;
Yun, Mijin ;
Lee, Jong Doo ;
Kim, Joo Hang ;
Lee, Jae-Hoon .
YONSEI MEDICAL JOURNAL, 2013, 54 (06) :1377-1383
[8]   Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study [J].
Dong, Qian ;
Yang, Xiang-hong ;
Zhang, Yao ;
Jing, Wei ;
Zheng, Li-qiang ;
Liu, Yun-peng ;
Qu, Xiu-juan .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
[9]   The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM [J].
Edge, Stephen B. ;
Compton, Carolyn C. .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) :1471-1474
[10]   Role of FDG-PET/CT in Diagnosis, Staging, Response to Treatment, and Prognosis of Pancreatic Cancer [J].
Grassetto, Gaia ;
Rubello, Domenico .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (02) :111-114
1234